[18F]ZDG2 First-in-Human PET Imaging in PAH
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07934264. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
First-in-Human PET Imaging of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension Using [18F]ZDG2: Safety, Biodistribution, Dosimetry and Pharmacokinetics
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to find out whether \[18F\]ZDG2 can detect early blood vessel changes in people with pulmonary arterial hypertension (PAH). The study will help answer this question: Can a positron emission tomography (PET) scan using \[18F\]ZDG2 help identify PAH? Participants will: * Receive one or two doses of the study tracer \[18F\]ZDG2 and have a PET/CT scan after each dose * Provide blood and urine samples * Tell the study team about any side effects or symptoms you experience
Study identification
- NCT ID
- NCT07934264
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2026 (Estimated)
- Primary completion
- Apr 30, 2028 (Estimated)
- Completion
- Oct 31, 2028 (Estimated)
- Last update posted
- Nov 18, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Houston Methodist Research Institute | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07934264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.